Skip to main content

Iovance Biotherapeutics, Inc.

corporate_fare Company Profile

Iovance Biotherapeutics, Inc.

IOVA·NASDAQ·Life Sciences·CIK 0001425205

Iovance Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company focused on treating cancer through tumor infiltrating lymphocyte (TIL) cell therapies. The company aims to be a global leader in innovating, developing, and delivering these therapies for patients with solid tumor cancers. TIL cell therapies work by using an individual's immune system to recognize and destroy cancer cells unique to each patient. These therapies are manufactured using centralized, scalable, and proprietary processes that rejuvenate and multiply each patient's polyclonal T cells into billions. Iovance was founded to expand upon TIL cell therapy initially developed at academic research centers, including the National Cancer Institute (NCI). The company's multi-center trials, scalable manufacturing, regulatory approvals, and commercial infrastructure have made TIL cell therapy a commercially viable treatment accessible to thousands of cancer patients. Iovance's commercial products include Amtagvi® (lifileucel) and Proleukin® (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi® treatment regimen and other applications. Amtagvi® is the first one-time, individualized T cell therapy for a solid tumor cancer, specifically for adult patients with previously treated advanced, unresectable, or metastatic melanoma. It is administered as part of a regimen that includes lymphodepletion and a short course of Proleukin®. Amtagvi® is approved in the U.S. and Canada. The company plans to launch into additional markets with a high prevalence of advanced melanoma, with potential approvals pending in the United Kingdom (UK) and Australia in the first half of 2026, and Switzerland in 2027. In the European Union (EU), Iovance withdrew its initial marketing authorization application (MAA) in July 2025 and is working with the European Medicines Agency (EMA) to resubmit a centralized MAA in 2026.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 29 items for IOVA at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Iovance Projects $350-370M 2026 Revenue, IOV-END-201 Shows 40% ORR; UK Amtagvi Application Withdrawn
  • Iovance Reports Strong Q1 Revenue Growth, Reduced Loss, Positive Clinical Data, and FY26 Guidance
  • Iovance Reports Strong Q1 Revenue Growth and Reduced Net Loss, Bolstered by ATM Capital Raise
  • Iovance Biotherapeutics Misses Q1 Profit Estimates, Operating Income Falls Short
  • Iovance Seeks Shareholder Approval for Substantial 150M Share Authorized Stock Increase

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$263.5M
Net Income
-$390.98M
Diluted EPS
-$1.09
Op. Cash Flow
-$302.41M
Free Cash Flow
-$336.24M
Gross Profit
$90.32M
Operating Income
-$403.36M
Cash & Equivalents
$163.08M
Debt / Equity
0.00×
Net Margin
-148.4%
Shares Outstanding
411.94M sh
Source: 10-K · filed 2026-02-24 · accession 0001104659-26-018899
$6.99 +1.25% today
52-week range · as of 2026-11-05 $1.76 – $15.37
Market cap
$3.19B
Volume
13.7M (1.0× avg)
3-mo avg 13.7M
Live data · 2026-11-22 12:54 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed IOVA - Filings & News (Page 2)

IOVA
May 07, 2026, 4:05 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $3.59
Real-time Price: $6.99 info
Change: +$3.40 (+95%) info
Market Cap: $3.192B info
IOVA
May 07, 2026, 9:18 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.42
Real-time Price: $6.99 info
Change: +$3.57 (+104%) info
Market Cap: $3.192B info
IOVA
May 07, 2026, 9:16 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $3.39
Real-time Price: $6.99 info
Change: +$3.60 (+106%) info
Market Cap: $3.192B info
IOVA
May 07, 2026, 7:05 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $3.30
Real-time Price: $6.99 info
Change: +$3.69 (+112%) info
Market Cap: $3.192B info
IOVA
Apr 28, 2026, 5:01 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $3.38
Real-time Price: $6.99 info
Change: +$3.61 (+107%) info
Market Cap: $3.192B info
IOVA
Apr 17, 2026, 5:01 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $3.84
Real-time Price: $6.99 info
Change: +$3.15 (+82%) info
Market Cap: $3.192B info
IOVA
Mar 05, 2026, 3:04 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $4.41
Real-time Price: $6.99 info
Change: +$2.58 (+58%) info
Market Cap: $3.192B info
IOVA
Feb 24, 2026, 9:35 AM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $3.38
Real-time Price: $6.99 info
Change: +$3.61 (+107%) info
Market Cap: $3.192B info
IOVA
Feb 24, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.05
Real-time Price: $6.99 info
Change: +$3.94 (+129%) info
Market Cap: $3.192B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets